文献速递前列腺癌

阿托伐他汀治疗去势抵抗性前列腺癌的II期概念验证研究

Phase II proof-of-concept study of atorvastatin in castration-resistant prostate cancer.
PubMed 文献 · BJU Int · 2022-08-12

SPECTRE试验是一项为期6周的单臂II期概念验证治疗试验,在去势抵抗性前列腺癌(CRPC)患者中联合阿托伐他汀与雄激素剥夺治疗,主要终点为6周内任何时间前列腺特异性抗原(PSA)较基线下降≥50%的患者比例。预定中期分析时12例中1例达到主要终点,未达到继续招募所需的≥2例;全部12例血清胆固醇显著下降,12例中6例PSA速度下降,提示疾病稳定;代谢组学分析识别色氨酸为与治疗反应相关的主要代谢物。

要点

  • SPECTRE试验中12例CRPC患者仅1例PSA较基线下降≥50%,未达到继续招募所需的≥2例。
  • 全部12例患者接受他汀治疗后血清胆固醇水平显著下降。
  • 12例中6例他汀治疗后PSA速度下降,提示疾病稳定;色氨酸为与反应相关的主要代谢物。

核心结论

  • SPECTRE研究数据首次提供他汀介导效应对CRPC的证据及疾病稳定的早期迹象。
  • 数据提示色氨酸代谢改变可能与肿瘤反应相关。

研究设计与样本

  • SPECTRE试验是一项为期6周的概念验证单臂II期治疗试验,联合阿托伐他汀与雄激素剥夺治疗CRPC患者(不论转移状态)。
  • 主要终点为6周阿托伐他汀用药期间任何时间PSA较基线下降≥50%的患者比例(PSA反应)。
  • 探索性终点包括PSA速度和质谱法识别的血清代谢物。

主要发现

  • 预定中期分析时12例中1例PSA较基线下降≥50%(主要终点),继续招募需≥2例满足主要终点。
  • 全部12例患者他汀治疗后血清胆固醇水平显著下降。
  • 全部患者研究前PSA速度相当,他汀治疗后12例中6例PSA速度下降,提示疾病稳定。
  • 对每周连续血样的无偏代谢组学分析识别色氨酸为与患者对他汀反应相关的主要代谢物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To test for evidence of statin-mediated effects in patients with castration-resistant prostate cancer (CRPC) as post-diagnosis use of statins in patients with prostate cancer is associated with favourable survival outcome. PATIENTS AND METHODS: The SPECTRE trial was a 6-weeks-long proof-of-concept single-arm Phase II treatment trial, combining atorvastatin and androgen deprivation therapy in patients with CRPC (regardless of metastatic status), designed to test for evidence of statin-mediated effects in patients with CRPC. The primary study endpoint was the proportion of patients achieving a ≥50% drop from baseline in prostate-specific antigen (PSA) levels at any time over the 6-week period of atorvastatin medication (PSA response). Exploratory endpoints include PSA velocity and serum metabolites identified by mass spectrometry . RESULTS: At the scheduled interim analysis, one of 12 patients experienced a ≥50% drop in PSA levels (primary endpoint), with ≥2 patients satisfying the primary endpoint required for further recruitment. All 12 patients experienced substantial falls in serum cholesterol levels following statin treatment. While all patients had comparable pre-study PSA velocities, six of 12 patients showed decreased PSA velocities after statin treatment, suggestive of disease stabilization. Unbiased metabolomics analysis on serial weekly blood samples identified tryptophan to be the dominant metabolite associated with patient response to statin. CONCLUSIONS: Data from the SPECTRE study provide the first evidence of statin-mediated effects on CRPC and early sign of disease stabilization. Our data also highlight the possibility of altered tryptophan metabolism being associated with tumour response.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Rushworth LK, Loveridge C, Salji M, et al. Phase II proof-of-concept study of atorvastatin in castration-resistant prostate cancer. BJU Int. 2022. PMID: 35844167. doi:10.1111/bju.15851

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。